Replies to post #551853 on NorthWest Biotherapeutics Inc (NWBO)

[dmb2]

beachhyena, I agree that the ASM is the pivot point where shareholders should be given clear plans. Now everyone knows the positive trial results which took additional years to produce. And, since NWBO was working toward the approval pathway during this additional significant time they should have been well prepared to advance rapidly post P3 TLD, IMO.

I see where some regulatory hurdles have been clearing their path just in advance of their steps like a snowplow, but I expect a very informative ASM this time around. NWBO is now much less vulnerable, has the medical community providing tailwinds, and should be in commercialization planning mode. Good leadership is accomplished on a continuum scale. They should shift gears. I see the P3 TLD as the pivot event and the ASM as the announcement of that pivot.

GLTA